Weekly semaglutide reduces craving in adults with alcohol use disorder
Weekly doses of the glucagon‐like peptide 1 (GLP‐1) receptor agonist semaglutide resulted in reduced alcohol craving relative to placebo in adults with alcohol use disorder (AUD), a 9‐week randomized trial has found. Use of semaglutide also resulted in improvement in some but not all alcohol use outcomes compared with placebo. Study results were published online Feb. 12. 2025, in JAMA Psychiatry .
Publication Details
- Journal
- The Brown University Psychopharmacology Update
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1002/pu.31307
- Primary Topic
- Alcohol Consumption and Health Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00